PDL1 A549
CBP74245
I. Background | |
腫瘤細(xì)胞可以借助免疫檢查點(diǎn)受體逃避機(jī)體免疫系統(tǒng)的識別和殺傷,因此阻斷免疫檢 查點(diǎn)受體可能是一種廣泛有效的腫瘤免疫治療方法。目前,抗 PD-1/PD-L1 抗體雖然比較 成熟,與抗 CTLA4 抗體類似,但由于存在耐藥性,患者的總體有效率較低,因此尋找新 的腫瘤免疫治療靶點(diǎn)迫在眉睫。 |
|
II. Description | |
PDL1 A549藥靶模型很好的模擬了體內(nèi) PDL1的信號轉(zhuǎn)導(dǎo)過程,原理見下圖所示。
|
|
III. Introduction | |
Expressed gene: | PDL1 |
Stability: | 32 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.) |
Freeze Medium: | 90% FBS+10% DMSO |
Culture Medium: | F12K+10%FBS+200μg/ml hygromycin |
Mycoplasma Testing: | Negative |
Storage: | Liquid nitrogen |
Application(s): | Binding Assay,FACS |
IV. Representative Data |
Figure 2. Recombinant PDL1 A549 stably expressing PDL1.